Aerolef
Navigation Links
Aerolef in Medical Technology
MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM
BioSciences Inc. , an oncology company that identifies, develops
and commercializes differentiated products for patients worldwide,
today announced top-line results from its randomized,
placebo-controlled Phase IIb trial of AeroLEF(TM) in o...
- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
Aerolef in Biological Technology
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre......, and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...... - Dr. Ali Raza To Lead Further Development Of aerolef As President Of aerolef Division - MISSISSAUGA, ON, June 19 /PRNewswire-...of the Phase II clinical development of AeroLEF. aerolef is being developed as a novel and effective approa...
Other TagsAspirationAtrophyOther Contentsfurniturefurniturefurniturefurniturefurunclegalactosegalactosegalactosemiagalliumgallbladdergallbladdergallbladdergallgallgallgall
AspergillosisAsphyxiaAspirationAstigmatismAtelectasisAtheroembolicAtresiaAtopyAthetosisAtrophicAtrophyAudiologyAuscultationAutosomal
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... Calif., Dec. 14 Tough Enough To Wear ... breast cancer, celebrated its fifth anniversary at the ... the Wrangler National Finals Rodeo (Wrangler NFR) in ... with rough-and-tumble rodeo cowboys, the support of the ... the sold-out crowd sported pink shirts, hats, bracelets ...
(Date:12/14/2009)... Staff , ... La Jolla, Calif. (Vocus) -- The ... MD, as the new chief of staff of the 372-bed facility. ... team on Jan. 1, 2010. , , , , ,During his ... Scripps La Jolla’s administrative staff and its board of directors. Dr. ...
(Date:12/14/2009)... Critical to Stemming Tide of Tens of Thousands ... WASHINGTON, Dec. 14 Legislation approved by ... will be crucial in helping to reduce tens ... each year in the United States, the ... The provision was included in the FY ...
(Date:12/14/2009)... Dec. 14 When Kurth Krause, an ... instructions for landing on the moon, he,was confident ... anything.,Years later, Kurth realized there was one thing ... kidney transplant and even though dialysis machines,would keep ... a transplant. Kurth,wrote: "My wife is 69 and ...
Breaking Medicine News(10 mins):Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3[0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement[0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary[1] New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla[0] NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange[0] 69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger
(Date:12/11/2009)... Ivy Pike, an associate professor of anthropology at the ... rural northern Kenya to understand how violence shapes the ... The results of her and her colleagues, research," Documenting ... communities of northern Kenya: A conceptual framework," is currently ... and Medicine , in collaboration with the British medical ...
(Date:12/11/2009)... Arno Motulsky, the senior editor of the 4th edition ... Human Genetics, was recently given the Victor A. McKusick ... contributions to the field of human genetics, was presented ... American Society of Human Genetics on 24 October 2009 ... Medicine and Genome Sciences at the University of Washington ...
(Date:12/11/2009)... of weight by eating less and exercising more improved ... School of Medicine in St. Louis. , The results ... 2009, issue of the Journal of the American ... to improvement in four key measures of heart and ... included decreased thickness of heart muscle, improved pumping and ...
Breaking Biology News(10 mins):UA-led study grapples with health effects of low-intensity warfare 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 53879 1NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 53879 2NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 53879 3NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 53879 4NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 53879 5Thirteen Courage Center Youth Athletes Take Top Honors in National Sports Competition 53874 1Thirteen Courage Center Youth Athletes Take Top Honors in National Sports Competition 53874 2Thirteen Courage Center Youth Athletes Take Top Honors in National Sports Competition 53874 3UC design research points the way so you wont get lost at the hospital 53871 1UC design research points the way so you wont get lost at the hospital 53871 2UC design research points the way so you wont get lost at the hospital 53871 3UC design research points the way so you wont get lost at the hospital 53871 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |